In mice, GDF-15 increases satiety and reduces food intake through actions in the central nervous system [99]
Glucagon-like-peptide-1 (GLP-1) agonists are a group of drugs approved for use in management of type-2 diabetes and obesity
So its pretty likely that theres not going to be a real effect on these other modalities, at least in the initial treatment phase. Dasgupta hopes to see GLP-1s used alongside current treatments, like CPAP
The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Because even as branded drugs become more available and potentially cheaper, the same coverage restrictions, BMI cutoffs, and off-label barriers remain
[21] [22] Regarding GLP-1 medications and lymphoedema , there is currently insufficient evidence to recommend their use specifically for this condition